BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17483333)

  • 1. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells.
    Gu X; Zerbini LF; Otu HH; Bhasin M; Yang Q; Joseph MG; Grall F; Onatunde T; Correa RG; Libermann TA
    Cancer Res; 2007 May; 67(9):4219-26. PubMed ID: 17483333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
    Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
    Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor metastasis suppressor functions of Ets transcription factor through integrin β3-mediated signaling pathway.
    Pal M
    J Cell Physiol; 2019 Nov; 234(11):20266-20274. PubMed ID: 30982973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate derived ETS factor (PDEF): a putative tumor metastasis suppressor.
    Steffan JJ; Koul HK
    Cancer Lett; 2011 Nov; 310(1):109-17. PubMed ID: 21764212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells.
    Tsui KH; Lin YH; Chung LC; Chuang ST; Feng TH; Chiang KC; Chang PL; Yeh CJ; Juang HH
    Cancer Lett; 2016 May; 375(1):142-151. PubMed ID: 26965996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression.
    Feldman RJ; Sementchenko VI; Gayed M; Fraig MM; Watson DK
    Cancer Res; 2003 Aug; 63(15):4626-31. PubMed ID: 12907642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel role for PDEF in epithelial cell migration and invasion.
    Gunawardane RN; Sgroi DC; Wrobel CN; Koh E; Daley GQ; Brugge JS
    Cancer Res; 2005 Dec; 65(24):11572-80. PubMed ID: 16357167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOXB13 regulates the prostate-derived Ets factor: implications for prostate cancer cell invasion.
    Kim IJ; Kang TW; Jeong T; Kim YR; Jung C
    Int J Oncol; 2014 Aug; 45(2):869-76. PubMed ID: 24898171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer.
    Turner DP; Moussa O; Sauane M; Fisher PB; Watson DK
    Cancer Res; 2007 Feb; 67(4):1618-25. PubMed ID: 17308102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.
    Sood AK; Saxena R; Groth J; Desouki MM; Cheewakriangkrai C; Rodabaugh KJ; Kasyapa CS; Geradts J
    Hum Pathol; 2007 Nov; 38(11):1628-38. PubMed ID: 17521701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signatures of prostate-derived Ets factor (PDEF) in cancer.
    Mahajan N
    Tumour Biol; 2016 Nov; 37(11):14335-14340. PubMed ID: 27612480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo.
    Ghadersohi A; Pan D; Fayazi Z; Hicks DG; Winston JS; Li F
    Breast Cancer Res Treat; 2007 Mar; 102(1):19-30. PubMed ID: 16897429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
    Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
    Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDEF in prostate cancer.
    Sood AK; Kim H; Geradts J
    Prostate; 2012 May; 72(6):592-6. PubMed ID: 21796651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-Derived Ets Factor (PDEF) Inhibits Metastasis by Inducing Epithelial/Luminal Phenotype in Prostate Cancer Cells.
    Wang F; Koul S; Shanmugam PST; Dong Q; Koul HK
    Mol Cancer Res; 2018 Sep; 16(9):1430-1440. PubMed ID: 29848555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression.
    Turner DP; Findlay VJ; Moussa O; Semenchenko VI; Watson PM; LaRue AC; Desouki MM; Fraig M; Watson DK
    Prostate; 2011 Dec; 71(16):1723-35. PubMed ID: 21446014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDEF downregulates stathmin expression in prostate cancer.
    Sabherwal Y; Mahajan N; Helseth DL; Gassmann M; Shi H; Zhang M
    Int J Oncol; 2012 Jun; 40(6):1889-99. PubMed ID: 22378487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells.
    Sabherwal Y; Mahajan N; Zhang M
    Oncol Rep; 2013 Oct; 30(4):1985-8. PubMed ID: 23921628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells.
    Kim CJ; Sakamoto K; Tambe Y; Inoue H
    Int J Oncol; 2011 Jun; 38(6):1759-66. PubMed ID: 21468544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells.
    Thelen P; Jarry H; Ringert RH; Wuttke W
    Planta Med; 2004 May; 70(5):397-400. PubMed ID: 15124082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.